Clinical Trials Browser

Recurrence × Doxorubicin × Plasma cell × Clear all

NCT02206425 2023-10-31

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

Phase 1/2 Completed

Multiple Myeloma, Recurrence

NCT00441168 2014-03-21

Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma

Phase 2 Terminated

30 enrolled 14 charts

Multiple Myeloma, Neoplasms, Recurrence